<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929460</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT01929460</nct_id>
  </id_info>
  <brief_title>A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration</brief_title>
  <official_title>A Prospective, Placebo-controlled Trial on the Use of Antibiotics for Pancreatic Cyst Aspiration: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that a single dose of antibiotics at time of EUS-guided pancreatic cyst
      aspiration is equally effective to the usual regimen of 3 days of post-procedural
      antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the increased use of cross sectional imaging, there appears to be an increasing
      prevalence of pancreatic cysts being incidentally discovered.

      A critical step in the workup of pancreas cysts is to determine whether the cyst is mucinous
      or non-mucinous, through a procedure called endoscopic ultrasound - fine needle aspiration
      (EUS-FNA).

      Current guidelines suggest the use of antibiotics in cyst aspiration, usually 3 days after
      the procedure. However, these recommendations are based on limited data from over 15 years
      ago. More recent retrospective observations suggest equivalent safety when little, or even no
      antibiotics are given.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</measure>
    <time_frame>At 2 weeks after procedure</time_frame>
    <description>first time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</measure>
    <time_frame>At 4 weeks after procedure</time_frame>
    <description>second time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</measure>
    <time_frame>At 6 weeks after procedure</time_frame>
    <description>third and final time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions</measure>
    <time_frame>six weeks</time_frame>
    <description>Number of participants with adverse drug reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related Complications</measure>
    <time_frame>six weeks after procedure</time_frame>
    <description>Number of patients with procedure-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cyst Fluid Carcinoembryonic Antigen (CEA)</measure>
    <time_frame>six weeks</time_frame>
    <description>Mean cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cyst Fluid Amylase</measure>
    <time_frame>six weeks</time_frame>
    <description>Mean cyst fluid amylase for classification of mucinous cystic lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Cyst Fluid Carcinoembryonic Antigen (CEA)</measure>
    <time_frame>six weeks</time_frame>
    <description>Median cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Cyst Fluid Amylase</measure>
    <time_frame>six weeks</time_frame>
    <description>Median cyst fluid amylase for classification of mucinous cystic lesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Pancreatic Cysts</condition>
  <arm_group>
    <arm_group_label>Drug (Standard group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>ciprofloxacin oral capsule (one capsule twice a day for 3 days)</description>
    <arm_group_label>Drug (Standard group)</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (for ciprofloxacin)</intervention_name>
    <description>oral placebo capsule (one capsule twice a day for 3 days)</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>sugar pill formulated to mimic oral ciprofloxacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the age of 18-90 who present for an EUS / pancreas cyst evaluation

        Exclusion Criteria:

          -  Patients outside the age range

          -  Patient-related factors (unable to provide consent, unable to understand English,
             allergic to cipro)

          -  High-risk patients for infective endocarditis

          -  Bacterial infection or use of antibiotics within 6 weeks of EUS

          -  Pancreatitis within the past 6 months

          -  Underlying immunosuppression (for example, uncontrolled diabetes - such as hemoglobin
             A1c above 7 or glucose &gt; 180; renal failure; cirrhosis; pre-existing malignancy
             especially hematologic malignancy such as leukemia / lymphoma / multiple myeloma;
             HIV/AIDS)

          -  Currently taking immunosuppressive medications (for conditions such as rheumatoid
             arthritis, inflammatory bowel disease, organ transplant)

          -  Radiographic or endosonographic evidence of cyst cavity debris / necrotic debris

          -  Severe systemic disease (for example, NYHA class III or IV heart failure,
             oxygen-dependent COPD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Kwok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente, Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobson BC, Baron TH, Adler DG, Davila RE, Egan J, Hirota WK, Leighton JA, Qureshi W, Rajan E, Zuckerman MJ, Fanelli R, Wheeler-Harbaugh J, Faigel DO; American Society for Gastrointestinal Endoscopy. ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc. 2005 Mar;61(3):363-70.</citation>
    <PMID>15758904</PMID>
  </reference>
  <reference>
    <citation>Lee LS, Saltzman JR, Bounds BC, Poneros JM, Brugge WR, Thompson CC. EUS-guided fine needle aspiration of pancreatic cysts: a retrospective analysis of complications and their predictors. Clin Gastroenterol Hepatol. 2005 Mar;3(3):231-6.</citation>
    <PMID>15765442</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>October 7, 2015</results_first_submitted>
  <results_first_submitted_qc>November 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2015</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciprofloxacin (Standard Group)</title>
          <description>Standard group: this group will receive three days of oral antibiotics after their Endoscopic Ultrasound (EUS)-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Intervention Group)</title>
          <description>Intervention group: this group will receive three days of oral PLACEBO after their Endoscopic Ultrasound (EUS)-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciprofloxacin (Standard Group)</title>
          <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Intervention Group)</title>
          <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="40" upper_limit="85"/>
                    <measurement group_id="B2" value="68.5" lower_limit="50" upper_limit="82"/>
                    <measurement group_id="B3" value="68.3" lower_limit="40" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of fine needle aspiration (FNA) passes</title>
          <units>passes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.46" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B2" value="1.38" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="1.42" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</title>
        <description>first time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
        <time_frame>At 2 weeks after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</title>
          <description>first time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</title>
        <description>second time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
        <time_frame>At 4 weeks after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</title>
          <description>second time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</title>
        <description>third and final time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
        <time_frame>At 6 weeks after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration</title>
          <description>third and final time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Drug Reactions</title>
        <description>Number of participants with adverse drug reactions</description>
        <time_frame>six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Reactions</title>
          <description>Number of participants with adverse drug reactions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure-related Complications</title>
        <description>Number of patients with procedure-related complications</description>
        <time_frame>six weeks after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure-related Complications</title>
          <description>Number of patients with procedure-related complications</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cyst Fluid Carcinoembryonic Antigen (CEA)</title>
        <description>Mean cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions</description>
        <time_frame>six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cyst Fluid Carcinoembryonic Antigen (CEA)</title>
          <description>Mean cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.1" lower_limit="0.2" upper_limit="1982"/>
                    <measurement group_id="O2" value="2466.2" lower_limit="0.2" upper_limit="24056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cyst Fluid Amylase</title>
        <description>Mean cyst fluid amylase for classification of mucinous cystic lesions</description>
        <time_frame>six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cyst Fluid Amylase</title>
          <description>Mean cyst fluid amylase for classification of mucinous cystic lesions</description>
          <units>Units/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3729" lower_limit="30" upper_limit="7200"/>
                    <measurement group_id="O2" value="1944.5" lower_limit="28" upper_limit="7200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Cyst Fluid Carcinoembryonic Antigen (CEA)</title>
        <description>Median cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions</description>
        <time_frame>six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Cyst Fluid Carcinoembryonic Antigen (CEA)</title>
          <description>Median cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="3.4" upper_limit="74.5"/>
                    <measurement group_id="O2" value="24.9" lower_limit="0.35" upper_limit="248.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Cyst Fluid Amylase</title>
        <description>Median cyst fluid amylase for classification of mucinous cystic lesions</description>
        <time_frame>six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin (Standard Group)</title>
            <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Intervention Group)</title>
            <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Cyst Fluid Amylase</title>
          <description>Median cyst fluid amylase for classification of mucinous cystic lesions</description>
          <units>Units/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4006.5" lower_limit="167.5" upper_limit="7200"/>
                    <measurement group_id="O2" value="239" lower_limit="144" upper_limit="2930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were prospectively monitored during the study period (1/1/2014-12/31/2014) at 2, 4, 6 weeks post procedure, or if the patient contacted the on-call research staff at any time after hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug (Standard Group)</title>
          <description>Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
Ciprofloxacin 500mg by mouth twice a day for three days.
Ciprofloxacin</description>
        </group>
        <group group_id="E2">
          <title>Intervention Group</title>
          <description>Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
Oral Placebo, one cap twice a day for three days.
Placebo (for ciprofloxacin)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>pancreatitis</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitis</sub_title>
                <description>one patient in the placebo arm was admitted for post-procedure pancreatitis. Recovered without incident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>pain</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <description>2 cases deemed unrelated to the procedure (1, nephrolithiasis; 1, chronic abdominal pain).
1 case deemed probably unrelated
1 case deemed possibly related but resolved uneventfully with conservative measures only</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karl Kwok, MD</name_or_title>
      <organization>Kaiser Permanente, Los Angeles Medical Center</organization>
      <phone>800-954-8000</phone>
      <email>regional-research-committee@kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

